在实验和计算研究的基础上,提出了[2 t + 2 i + 2 i ]硫代酮和亚胺环化的立体化学模型和机理见解。在涉及环亚胺的[2 t + 2 i + 2 i ]环中,由单取代硫代乙烯酮和环亚胺生成的两性离子中间体通过第二亚胺分子经历逐步的亲核内加成/ Si面攻击路径,最初为( 2,4)-顺式-(4,5)-顺式-[2 t + 2 i + 2 i]年环,在碱性反应条件下可完全游离为相应的(2,4)-顺式-(4,5)-反式环化产物。硫代-施陶丁格环加成的环选择性取决于硫代烯酮和亚胺的取代基。比较了施陶丁格,硫代施陶丁格和磺胺施陶丁格中间体的反应性和环选择性。
THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS
申请人:Chen Li
公开号:US20100152203A1
公开(公告)日:2010-06-17
Compounds of the formula I:
or a pharmaceutically acceptable salt thereof, wherein, R
1
is optionally substituted thiadiazolyl, and R
2
, R
3
, R
4
, R
5
, R
6
, R
7
and R
8
are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X
3
and/or a P2X
2/3
receptor antagonists and methods of making the compounds.
Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists
申请人:Roche Palo Alto LLP
公开号:US08119644B2
公开(公告)日:2012-02-21
Compounds of the formula I:
or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted thiadiazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
[2t + 2i + 2i] annulations of thioketenes and imines on the basis of experimental and computational investigations. In the [2t + 2i + 2i] annulations involving cyclicimines, the zwitterionic intermediates generated from monosubstituted thioketenes and the cyclicimines undergo a stepwise nucleophilic endo-addition/Si-face attack pathway with a second imines molecule, giving initially (2,4)-cis-(4,5)-cis-[2t
在实验和计算研究的基础上,提出了[2 t + 2 i + 2 i ]硫代酮和亚胺环化的立体化学模型和机理见解。在涉及环亚胺的[2 t + 2 i + 2 i ]环中,由单取代硫代乙烯酮和环亚胺生成的两性离子中间体通过第二亚胺分子经历逐步的亲核内加成/ Si面攻击路径,最初为( 2,4)-顺式-(4,5)-顺式-[2 t + 2 i + 2 i]年环,在碱性反应条件下可完全游离为相应的(2,4)-顺式-(4,5)-反式环化产物。硫代-施陶丁格环加成的环选择性取决于硫代烯酮和亚胺的取代基。比较了施陶丁格,硫代施陶丁格和磺胺施陶丁格中间体的反应性和环选择性。
SCHAUMANN E.; GRABLEY F.-F., LIEBIGS ANN. CHEM., 1979, NO 11, 1746-1755